Colorectal cancer

Jordanian royalty to grace Prevent Cancer Foundation 29th Annual Gala

Retrieved on: 
Wednesday, September 6, 2023
Pillar, Firefighter, National Breast Cancer Coalition, National Building Museum, Cancer, Woman, Research, Royal Highness, RSVP, Government, Congress, Affordable Care Act, Risk, Colorectal cancer, Community, Sport, Gala, Princess Ghida Talal, Birth control, Tobacco

The 2022 Gala was a record-breaking event, raising over $2.2 million for cancer prevention and early detection efforts.

Key Points: 
  • The 2022 Gala was a record-breaking event, raising over $2.2 million for cancer prevention and early detection efforts.
  • Continuing with tradition, the Foundation will present the annual Cancer Champion awards.
  • Learn more about the Prevent Cancer Annual Gala .
  • The 2023 Prevent Cancer Gala thanks its top sponsors:

Geneoscopy CEO Andrew Barnell to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Retrieved on: 
Wednesday, September 6, 2023
General Health, Genetics, Health, Gastrointestinal disease, CRC, IBD, MBA, Research, RNA, Inflammatory bowel disease, Incidence, PMA, Patient, Colorectal cancer, Medicine, Morgan, FDA, GI, Conference, Food, Pharmaceutical industry

Geneoscopy Inc. , a life sciences company focused on developing diagnostic tests for gastrointestinal health, today announced that Chief Executive Officer and Co-founder Andrew Barnell, MBA, will be presenting at the Morgan Stanley Global Healthcare Conference in New York, NY, on Monday, Sept. 11, at 2:15 p.m. Eastern Time.

Key Points: 
  • Geneoscopy Inc. , a life sciences company focused on developing diagnostic tests for gastrointestinal health, today announced that Chief Executive Officer and Co-founder Andrew Barnell, MBA, will be presenting at the Morgan Stanley Global Healthcare Conference in New York, NY, on Monday, Sept. 11, at 2:15 p.m. Eastern Time.
  • In addition, a recent study found that nearly 1 in 100 Americans suffer from IBD, with an estimated 2.39 million diagnosed.
  • “We are pleased to be presenting at Morgan Stanley’s Annual Global Healthcare Conference to share the promising market opportunities for our proprietary RNA biomarker platform and high-value diagnostic tests,” said Andrew Barnell, CEO and Co-founder of Geneoscopy.
  • These results are the highest reported for any noninvasive CRC screening test in any prospective registrational clinical study completed to date.

HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023

Retrieved on: 
Wednesday, September 6, 2023
Anantara New York Palace Budapest Hotel, Pancreatic cancer, Patent, Masonic Cancer Center, University, University of Minnesota, United States Patent and Trademark Office, Clinical trial, Cancer, Ageing, Gynecologic Oncology (journal), Research, Inflammation, Cell, MRC Laboratory of Molecular Biology, EDT, Trial of the century, Drug resistance, Molecular biology, National Cancer Institute, Professor, Patient, Division, Colorectal cancer, Department of Obstetrics and Gynecology (Massachusetts General Hospital), Immune system, Gynaecology, UMN, Principal, Lotte New York Palace Hotel, NCI, Notifiable disease, Immunosuppression, Natural killer T cell, Laboratory, Conference, Pharmaceutical industry, Vaccine, Obstetrics

On September 12, 2023, the Company will be meeting individual investors in person at the conference venue, the Lotte New York Palace Hotel in New York.

Key Points: 
  • On September 12, 2023, the Company will be meeting individual investors in person at the conference venue, the Lotte New York Palace Hotel in New York.
  • In addition, a pre-recorded, virtual Company update will be available on demand beginning at 7:00 a.m. EDT on September 11, 2023 for all who register for the conference.
  • Due to clinical protocol requirements, dosing of the remaining patients is expected to take place in the next 3 to 6 months.
  • Dr. Geller stated, “Our team is very excited to bring this clinical trial to patients who have recurrent cancer.

Dxcover Announces Expansion of Its Leadership Team to Support Advancement of its Multi-Cancer Liquid Biopsy Platform

Retrieved on: 
Wednesday, September 6, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Other Health, Business development, McRoberts, Doctor of Philosophy, WHO model list of essential in vitro diagnostics, Region (Europe), Abbott Laboratories, GE, Thermo Fisher Scientific, CCO, Commercial director, ASCO, Brain tumor, US Commercial Real Estate Index, Algorithm, Roche, Cancer, Colorectal cancer, Sanofi, Growth, BMS, Society, Management

Under his guidance, he will support the company’s business operations and long-term objectives, focusing on strategy, performance, and value creation.

Key Points: 
  • Under his guidance, he will support the company’s business operations and long-term objectives, focusing on strategy, performance, and value creation.
  • Andrews brings more than three decades of experience in the diagnostic space in various senior commercialization roles.
  • Prior to that he held leadership positions at The Bethesda Group, Thermo Fisher Scientific, GE, Roche Diagnostics, Abbott Diagnostics, amongst others.
  • Chick brings diagnostic and pharmaceutical commercialization experience as former CCO at Inivata and progressive leadership roles at Sanofi and BMS.

Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan

Retrieved on: 
Wednesday, September 6, 2023
Vitamins, Supplements, Insurance, Health Technology, Professional Services, Biotechnology, Managed Care, Health, General Health, Oncology, Survivor, DNA, Policy, Cancer, Geisinger Health System, National Comprehensive Cancer Network, GH, MRD, Medicare, Helmy Eltoukhy, Journal of the National Comprehensive Cancer Network, HIV disease progression rates, Patient, Colorectal cancer, Blood, Neoplasm, Recurrence, III, Disease, Pharmaceutical industry

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, announced today that Geisinger Health Plan now offers coverage for the Guardant Reveal™ minimal residual disease (MRD) test.

Key Points: 
  • Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, announced today that Geisinger Health Plan now offers coverage for the Guardant Reveal™ minimal residual disease (MRD) test.
  • “We are pleased that Geisinger Health Plan has taken this important step to make blood testing for residual disease more accessible to its members,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO.
  • The Geisinger Health Plan provides coverage for more than half a million members.
  • This policy decision adds to the payor coverage of Guardant Reveal, which received Medicare coverage in August 2022 and additional commercial payor coverage in July 2023.

EQS-News: Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market

Retrieved on: 
Tuesday, September 5, 2023
DNA, Partnership, Optimism, Fecal occult blood, CRC, Genetics, HLA, Infection, Cancer, Patient, Physician, Colorectal cancer, PHI, PCR, Airline, Pharmaceutical industry

Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market

Key Points: 
  • Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
    The issuer is solely responsible for the content of this announcement.
  • Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
    BERKELEY, US – MAINZ, Germany – September 5, 2023 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a strategic partnership with Ärztliches Labor Dr. Buhlmann, a move aimed at further strengthening its position in the German market.
  • The collaboration grants Mainz Biomed greater access to, and the potential for further expansion into Germany's private health insurance segment where ColoAlert®, its highly efficacious, and easy-to-use detection test for colorectal cancer (CRC), already receives reimbursement.
  • Established in 2006 and led by Dr. Annette Buhlmann, a seasoned expert with over 25 years of experience in laboratory medicine, Ärztliches Labor Dr. Buhlmann is a respected player in PCR-based analysis.

Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market

Retrieved on: 
Tuesday, September 5, 2023
DNA, Partnership, Optimism, Fecal occult blood, CRC, Genetics, HLA, Infection, Cancer, Patient, Physician, Colorectal cancer, PHI, PCR, Pharmaceutical industry

BERKELEY, Calif. and MAINZ, Germany, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a strategic partnership with Ärztliches Labor Dr. Buhlmann, a move aimed at further strengthening its position in the German market.

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a strategic partnership with Ärztliches Labor Dr. Buhlmann, a move aimed at further strengthening its position in the German market.
  • The collaboration grants Mainz Biomed greater access to, and the potential for further expansion into Germany's private health insurance segment where ColoAlert®, its highly efficacious, and easy-to-use detection test for colorectal cancer (CRC), already receives reimbursement.
  • Established in 2006 and led by Dr. Annette Buhlmann, a seasoned expert with over 25 years of experience in laboratory medicine, Ärztliches Labor Dr. Buhlmann is a respected player in PCR-based analysis.
  • Its comprehensive services include molecular diagnostics, genetics, HLA testing, and infectious disease assessments, catering to a diverse clientele spanning statutory and private insurance segments.

Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Friday, September 1, 2023
Exercise, IPO, AACR, Moffitt, Investment, TIL, Cancer, American Association for Cancer Research, Uveal melanoma, Research, TILS, Takeda Oncology, Patient, Administration, Colorectal cancer, Melanoma, SAN, Glomus tumor, Research institute, Research and development, R, Breast cancer, Pharmaceutical industry, Cryptocurrency, Turnstone

The shares began trading on the Nasdaq Global Market on July 21, 2023, under the ticker symbol “TSBX”.

Key Points: 
  • The shares began trading on the Nasdaq Global Market on July 21, 2023, under the ticker symbol “TSBX”.
  • Cash, Cash Equivalents and Short-Term Investments: As of June 30, 2023, cash, cash equivalents and short-term investments were $49.2 million.
  • The Company expects that the combined cash, cash equivalents and short-term investments will be sufficient to fund its operations into the second quarter of 2025.
  • Net Loss: Net loss for the three months ended June 30, 2023, was $21.5 million, compared to net income of $11.6 million for the second quarter of 2022.

Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test

Retrieved on: 
Friday, September 1, 2023
Oncology, Health, Health Technology, Clinical Trials, Research, Science, Biotechnology, GH, MRD, Cancer, Helmy Eltoukhy, MD, Patient, Colorectal cancer, COBRA, Health insurance

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today issued the following statement about the closure of COBRA, a minimum residual disease (MRD) study.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today issued the following statement about the closure of COBRA, a minimum residual disease (MRD) study.
  • The COBRA study was designed to evaluate the effectiveness of using MRD testing to improve clinical outcomes in patients with stage II colon cancer after curative-intent surgery with a planned final readout in 2026.
  • “We agree with the decision, based on the recent planned interim analysis, to close the COBRA study to new enrollees,” said Dr. Eagle.
  • Additionally, we have many ongoing studies that will demonstrate the effectiveness of our current MRD tests in colorectal cancer and other settings.”

ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers

Retrieved on: 
Thursday, August 31, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, HER2, Neoplasm, BTD, Medicine, ERBB2, NSCLC, Lung cancer, Doctor of Philosophy, AstraZeneca, IHC, ASCO, Gastrointestinal cancer, American Society of Clinical Oncology, MD, Patient, Colorectal cancer, Daiichi Sankyo, Douglas BTD Destroyer, Annual general meeting, Cancer, Immunohistochemistry, ADC, R, Biliary tract, Society, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, TSE, Breast cancer, Pharmaceutical industry, Medical imaging, Bachelor of Medicine, Bachelor of Surgery

ENHERTU is a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).

Key Points: 
  • ENHERTU is a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).
  • The new medicine needs to have shown encouraging preliminary clinical results that demonstrate substantial improvement on a clinically significant endpoint over available medicines.
  • ENHERTU previously received BTDs for three indications in breast cancer, including HER2 low metastatic breast cancer, second-line HER2 positive metastatic breast cancer and later-line HER2 positive metastatic breast cancer.
  • Two additional BTDs for ENHERTU were granted for HER2 (ERBB2) mutant metastatic non-small cell lung cancer (NSCLC) and HER2 positive metastatic gastric cancer.